Company news
Neurizon Therapeutics Limited news in 2016
Neurizon Therapeutics Limited's news releases, calls and decks from 2016, newest first.
Phase II Strategy Update
November 20, 2016
Phase II Canine Trial begins at University of Cambridge
September 18, 2016
Epichem achieves ISO 9001 2015 certification
September 15, 2016
MPL capsules shipped to centres in NSW & Qld for Phase II
September 12, 2016
Appendix 4E & Full Year Statutory Accounts 2016
August 31, 2016
Further Canine Trials to be Initiated in Australia
August 9, 2016
IP exchange with UNSW consolidates MPL patent position
August 2, 2016
Appendix 4C Quarterly & Brief Company Update - June 2016
July 28, 2016
Reformulated MPL capsules completed, Phase II to commence
July 10, 2016
University of Cambridge to begin Phase II Trial
June 26, 2016
Epichem Successful in AusTrade Grant
June 15, 2016
Appendix 4C Quarterly Report & Brief Company Update
April 28, 2016
First Two Patients in Canine Clinical Trial Begin Treatment
March 30, 2016
Completion of Share Sale Agreement and Drilling Commenced
March 30, 2016
Placement & Offer to Purchase Pela Resources
March 30, 2016
PharmAust to acquire rights to 3 oncology product platforms
March 30, 2016
Clarification on Record Date for SPP
March 30, 2016
Appendix 4D / Half Year Financial Report
March 30, 2016
Appendix 4D and Financial Report Dec 2012
March 30, 2016
PharmAust Fully Executes Share Sale Agreement With Pitney
March 30, 2016
Key Licence Provided by NewSouth Innovations
March 30, 2016
Important Discovery in Cancer Therapy
March 30, 2016
Clinical Study with PPL-1 Initiated following Approval
March 30, 2016
Appendix 4C - Quarterly
March 30, 2016
Appendix 4C
March 30, 2016
Human Cancer Trial Advancing To Second Patient
March 30, 2016
Clinical Trial in Dogs is now open for accrual
March 30, 2016
Appendix 4C Quarterly & Company Update
March 30, 2016
Strategy for Phase II Clinical Trial of Monepantel
March 7, 2016
Appendix 4D & Half Yearly Report and Accounts
February 28, 2016
Notice of Allowance received from USA Patent OffIce
February 11, 2016
Treatment of Canine Cancers
February 10, 2016
SPP Shortfall Heaily Oversubscribed
February 10, 2016
Share Sale Deed executed for the sale of Pela Resources
February 10, 2016
Shareholder Update - Human & Canine Trials
February 10, 2016
Second Dog Shows Suppression of Cancer Marker at Days 3 & 7
February 10, 2016
Second Cancer Patient Completes Course With Stable Disease
February 10, 2016
Response to ASX Volume Query
February 10, 2016
Response to ASX Price Query
February 10, 2016
Research Collaboration & Joint Patent with Japanese Company
February 10, 2016
Reduction of further Cancer Marker confirmed in Human Trial
February 10, 2016
Quarterly Report & Company Update
February 10, 2016
Placement
February 10, 2016
Phase I Trial at RAH Meets Safety & Cancer Marker End Points
February 10, 2016
PharmAust Receives $546K R&D Rebate from ATO
February 10, 2016
PharmAust Receives ATO Research & Development Rebate
February 10, 2016
PharmAust completes $3.14m Share Placement oversubscribed
February 10, 2016
PAA: PharmAust Finalises Investment in Oil and Gas Project
February 10, 2016
PAA: Lambouka 3D Seismic Fast Track Interpretation Completed
February 10, 2016
Notice of Annual General Meeting/Proxy Form
February 10, 2016
Decks in 2016
- PharmAust — Shareholder Meeting (November 2016)
Shareholder meeting · 19 slides · November 2016
- PharmAust — Investor Presentation (August 2016)
Investor deck · 19 slides · August 2016
- PharmAust — Non-Deal Roadshow (January 2016)
Roadshow · 21 slides · January 2016